Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Ontario Institute For Cancer Research (Oicr) maintains 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 4 distinct examiners and 4 distinct art units, showing a high degree of diversification in the examination process. This distribution suggests that each matter is being handled by a different individual at the patent office.
ELENISTE, PIERRE PAUL is the busiest examiner for this institute, currently overseeing 1 pending office action. Because there are 4 distinct examiners for the portfolio, the workload is evenly distributed across the 4 distinct art units. This structure implies that the Biotechnology & Pharmaceuticals filings cover a broad range of specific sub-disciplines, requiring the expertise of multiple specialized units.
The presence of 4 pending office actions indicates that the institute is engaging with a wide array of expertise. ELENISTE, PIERRE PAUL remains the busiest examiner with 1 pending office action, representing a single point of contact within this diverse prosecution landscape. This variety of examiners and art units ensures that each cancer research innovation is reviewed by a specialist in its specific field.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (25%) |
| Double-patenting only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ELENISTE, PIERRE PAUL | 1 | 35.4% | +31.1% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838651 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | ELENISTE, PIERRE PAUL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17612695 | PAN-CANCER TRANSCRIPTIONAL SIGNATURE | GOLDBERG, JEANINE ANNE | 366d overdue |
| 18838651 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | ELENISTE, PIERRE PAUL | — |
| 18288213 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | RZECZYCKI, PHILLIP MATTHEW | — |
| 18288219 | SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | NESTOR, DONNA MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18838651 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF BAX AND/OR BAK, COMPOSITIONS AND USES THEREOF | ELENISTE, PIERRE PAUL | 1622 | §103§112 | Non-Final OA | — | Pending | Aug 15, 2024 |
| 18288213 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | RZECZYCKI, PHILLIP MATTHEW | 1625 | DP | Final Rejection | — | Pending | Oct 25, 2023 |
| 18288219 | SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | NESTOR, DONNA MICHELLE | 1627 | §103DP | Final Rejection | — | Pending | Oct 25, 2023 |
| 17612695 | PAN-CANCER TRANSCRIPTIONAL SIGNATURE | GOLDBERG, JEANINE ANNE | 1682 | §112 | Non-Final OA | 366d overdue | Pending | Nov 19, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOntario Institute For Cancer Research (Oicr) has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Pierre Paul Eleniste has the most, with 1 of Ontario Institute For Cancer Research (Oicr)'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
